Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

John Nikitas

Assistant Professor

University of Pennsylvania

United States

Research Interests

Explore related searches

Professors in United States Professors in Medical Imaging Medical Imaging professors in United States

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (12)

Mark Litwin

Chair

University of California, Los Angeles

UNITED STATES

View details

Ariel E. Marciscano

Assistant Professor

Massachusetts General Hospital

UNITED STATES

View details

Ke Sheng

Professor and Vice Chair of Medical Physics

University of California, San Francisco

UNITED STATES

View details

Donatello Telesca

Professor

University of California Los Angeles Jonathan and Karin Fielding School of Public Health

UNITED STATES

View details

Emma Hall

Institute of Cancer Research

UNITED KINGDOM

View details

Wilma Heemsbergen

Researcher

Erasmus University Rotterdam

NETHERLANDS

View details

Joseph Osborne

Chief of Molecular Imaging and Therapeutics

Joan and Sanford I Weill Medical College of Cornell University

UNITED STATES

View details

Jie Deng

University of California, Los Angeles

UNITED STATES

View details

Luca Incrocci

Full professor

Erasmus University Rotterdam

NETHERLANDS

View details

Xavier Maldonado

Head of Department

Hospital Universitari Vall d'Hebron

SPAIN

View details

Robert B. Cameron

Professor

VA Greater Los Angeles Healthcare System

UNITED STATES

View details

JEREMIE CALAIS

David Geffen School of Medicine at UCLA

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

John Nikitas

Research Interests

Explore related searches

Articles (20)

Dose-escalated stereotactic body radiotherapy re-irradiation in patients with recurrent head and neck cancer: a prospective phase 2 study using automated non-coplanar volumetric modulated arc therapy

Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.

Phase 2 Prospective Trial of Retreatment with [<sup>177</sup>Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA.

Redefining Salvage Therapy for Localized Radiorecurrent Prostate Cancer-In More Ways Than One.

Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy.

Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen–defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy

Hypofractionated radiotherapy for prostate cancer (HYDRA)

The interplay between acute and late toxicity among patients receiving prostate radiotherapy

Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium

Concerns Regarding Follow-Up Duration and End Point Validity-Reply.

Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical Trial.

Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of <sup>177</sup>Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol.

Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial.

Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial.

Limitations in the meta-analysis of prostate radiotherapy-associated toxicity - Authors' reply.

Pathophysiology and Management of Chest Wall Pain after Surgical and Non-Surgical Local Therapies for Lung Cancer

Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study

Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.

Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)

Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy.

Collaborators (12)

Mark Litwin

Ariel E. Marciscano

Ke Sheng

Donatello Telesca

Emma Hall

Wilma Heemsbergen

Joseph Osborne

Jie Deng

Luca Incrocci

Xavier Maldonado

Robert B. Cameron

JEREMIE CALAIS

Make your next move.

John Nikitas

Research Interests

Explore related searches

Articles (20)

Dose-escalated stereotactic body radiotherapy re-irradiation in patients with recurrent head and neck cancer: a prospective phase 2 study using automated non-coplanar volumetric modulated arc therapy

Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.

Phase 2 Prospective Trial of Retreatment with [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA.

Redefining Salvage Therapy for Localized Radiorecurrent Prostate Cancer-In More Ways Than One.

Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy.

Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen–defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy

Hypofractionated radiotherapy for prostate cancer (HYDRA)

The interplay between acute and late toxicity among patients receiving prostate radiotherapy

Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium

Concerns Regarding Follow-Up Duration and End Point Validity-Reply.

Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical Trial.

Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of <sup>177</sup>Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol.

Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial.

Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial.

Limitations in the meta-analysis of prostate radiotherapy-associated toxicity - Authors' reply.

Pathophysiology and Management of Chest Wall Pain after Surgical and Non-Surgical Local Therapies for Lung Cancer

Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study

Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.

Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)

Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy.

Collaborators (12)

Mark Litwin

Ariel E. Marciscano

Ke Sheng

Donatello Telesca

Emma Hall

Wilma Heemsbergen

Joseph Osborne

Jie Deng

Luca Incrocci

Xavier Maldonado

Robert B. Cameron

JEREMIE CALAIS

Make your next move.

Phase 2 Prospective Trial of Retreatment with [<sup>177</sup>Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA.